Supply Pharmaceutical Raw Material Powder CAS 95233-18-4 Atovaquone

• Varieties: Synthesis Material Intermediates
• Type: Pharmaceutical Intermediates
• Storage Method: Cool Dry Place
• Appearance: Yellow Powder
• Quality: Industrial
• Certification: GMP, Hse, ISO 9001, USP, Bp
• Delivery Time: Within 24 Hours After Receiving The Payment
• Purity: >99%
• Transport Package: 25kg/Drum
• Specification: 25kg/500kg/1000kg
• Trademark: Jinan Andechem
• Origin: China
• HS Code: 29147000
• Production Capacity: 5ton/Month

Product Description

Product Name	Atovaquone
CAS No.	95233-18-4
MF	C22H19ClO3
Appearance	Yellow Powder
Packing	1KG/Bag
Specification	BP, USP, EP
Shelf life	2 Years

Atovaquone is an orally active antiprotozoal agent indicated for patients with mild to moderate AIDS-associated Pneumocystis carinii pneumonia who are intolerant to the fist-line therapy of trimethoprim-sulfamethoxazole. It is also under investigation as a treatment for malaria and AIDS-associated toxoplasmosis.
The hydroxynaphthoquinone atovaquone, which exhibits antimalarial and anti-Pneumocystis activity, is an electron transport inhibitor that causes depletion of the ATP pool. The primary effect is on the iron flavoprotein dihydro-orotate dehydrogenase, an essential enzyme in the production of pyrimidines. Mammalian cells are able to avoid undue toxicity by use of preformed pyrimidines. Dihydro-orotate dehydrogenase from Plasmodium falciparum is inhibited by concentrations of atovaquone that are very much lower than those needed to inhibit the Pneumocystis enzyme, raising the possibility that the antimicrobial consequences might differ in the two organisms. Although atovaquone was originally developed as a monotherapy for malaria, high level resistance readily emerges in Plasmodium falciparum when the drug is used alone. Consequently, atovaquone is now combined with proguanil.